Drug Combination Details
| General Information of the Combination (ID: C76567) | |||||
|---|---|---|---|---|---|
| Name | Arsenic trioxide NP Info | + | Gefitinib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Acute myeloid leukemia
[ICD-11: 2A60]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | ITGAM | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | NDUFA2 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | NB4 | CVCL_0005 | Acute promyelocytic leukemia | Homo sapiens | ||
| Experimental
Result(s) |
Gefitinib enhances arsenic trioxide (AS2O3)-induced differentiation of acute promyelocytic leukemia cell line. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Gefitinib enhances arsenic trioxide (AS2O3)-induced differentiation of acute promyelocytic leukemia cell line. Leuk Res. 2010 Nov;34(11):1501-5. | |||
